CA2752490C - Alpha-lactablumin complex with oleic acid and process for production thereof - Google Patents

Alpha-lactablumin complex with oleic acid and process for production thereof Download PDF

Info

Publication number
CA2752490C
CA2752490C CA2752490A CA2752490A CA2752490C CA 2752490 C CA2752490 C CA 2752490C CA 2752490 A CA2752490 A CA 2752490A CA 2752490 A CA2752490 A CA 2752490A CA 2752490 C CA2752490 C CA 2752490C
Authority
CA
Canada
Prior art keywords
lactalbumin
recombinant protein
biologically active
active complex
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2752490A
Other languages
English (en)
French (fr)
Other versions
CA2752490A1 (en
Inventor
Catharina Svanborg
Kenneth Hun Mok
Jenny Petterson-Kastberg
Ann-Kristin Mossberg
Original Assignee
Hamlet Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0900260A external-priority patent/GB0900260D0/en
Priority claimed from GB0906199A external-priority patent/GB0906199D0/en
Application filed by Hamlet Pharma AB filed Critical Hamlet Pharma AB
Publication of CA2752490A1 publication Critical patent/CA2752490A1/en
Application granted granted Critical
Publication of CA2752490C publication Critical patent/CA2752490C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2752490A 2009-01-09 2010-01-08 Alpha-lactablumin complex with oleic acid and process for production thereof Active CA2752490C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0900260A GB0900260D0 (en) 2009-01-09 2009-01-09 Complex and production process
GB0900260.1 2009-01-09
GB0906199A GB0906199D0 (en) 2009-04-09 2009-04-09 Complex and production process
GB0906199.5 2009-04-09
PCT/GB2010/050024 WO2010079362A1 (en) 2009-01-09 2010-01-08 Complex and production process

Publications (2)

Publication Number Publication Date
CA2752490A1 CA2752490A1 (en) 2010-07-15
CA2752490C true CA2752490C (en) 2020-03-10

Family

ID=42026257

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2752490A Active CA2752490C (en) 2009-01-09 2010-01-08 Alpha-lactablumin complex with oleic acid and process for production thereof

Country Status (8)

Country Link
US (1) US8796218B2 (https=)
EP (1) EP2385954B1 (https=)
JP (1) JP5679992B2 (https=)
CN (1) CN102348721A (https=)
AU (1) AU2010204178B2 (https=)
CA (1) CA2752490C (https=)
DK (1) DK2385954T3 (https=)
WO (1) WO2010079362A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8796218B2 (en) 2009-01-09 2014-08-05 Hamlet Pharma Ab Complex and production process
ES2613986T3 (es) 2010-11-24 2017-05-29 Hamlet Pharma Ab Complejo biológicamente activo y su preparación
HUE038910T2 (hu) 2012-08-09 2018-12-28 Hamlet Pharma Ab Profilaktikus és gyógytáp terápia
CN106636157A (zh) * 2016-09-01 2017-05-10 锦州医科大学 一种突变α‑乳清蛋白表达载体、制备方法及其应用
GB201621752D0 (en) * 2016-12-20 2017-02-01 Hamlet Pharma Ab Therapeutically active complexes
GB201707715D0 (en) * 2017-05-14 2017-06-28 Hamlet Pharma Ab Preperation of biologically active complexes
WO2021032807A1 (en) 2019-08-20 2021-02-25 Hamlet Pharma Ab Combination of a chemotherapeutic agent and alpha-lactoglubulin-oleic acid complex for cancer therapy
GB202015836D0 (en) 2020-10-06 2020-11-18 Hamlet Pharma Ab Compositions
GB202303177D0 (en) 2023-03-03 2023-04-19 Linnane Pharma Ab Method of predicting response to treatment
WO2025186107A1 (en) 2024-03-04 2025-09-12 Linnane Pharma Ab Therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1032596T3 (da) 1997-11-21 2007-09-10 Nya Hamlet Pharma Ab Fremgangsmåde til fremstilling af lactalbumin
GB9725126D0 (en) 1997-11-27 1998-01-28 Svanborg Catharina Therapeutic agents
AU5928599A (en) 1999-09-09 2001-04-10 Efa Sciences Llc. Methods for treating cell proliferative disorders including cancer
US6639089B2 (en) 2000-11-08 2003-10-28 Soda Aromatic Co., Ltd. Anticancer agents, perfumes or foods and drinks
GB0205347D0 (en) 2002-03-07 2002-04-24 Svanborg Catharina Biologically active complex
GB0508880D0 (en) * 2005-05-03 2005-06-08 Hamlet Pharma Ab Novel therapies and methods of screening for therapeutic compounds
US20080115228A1 (en) * 2006-11-15 2008-05-15 Yahoo! Inc. Rights engine
EP2094309A2 (en) 2006-11-17 2009-09-02 Nya Hamlet Pharma AB Alpha-lactalbumin composition
WO2008138348A1 (en) * 2007-05-09 2008-11-20 Nya Hamlet Pharma Ab Preparation of complexed lactalbumin
US8796218B2 (en) 2009-01-09 2014-08-05 Hamlet Pharma Ab Complex and production process
WO2010131237A1 (en) 2009-05-13 2010-11-18 Agriculture And Food Development Authority (Teagasc) A process for producing a biologically active globular protein complex
ES2613986T3 (es) 2010-11-24 2017-05-29 Hamlet Pharma Ab Complejo biológicamente activo y su preparación

Also Published As

Publication number Publication date
EP2385954B1 (en) 2013-04-03
WO2010079362A1 (en) 2010-07-15
JP5679992B2 (ja) 2015-03-04
US20120028883A1 (en) 2012-02-02
DK2385954T3 (da) 2013-06-17
EP2385954A1 (en) 2011-11-16
AU2010204178B2 (en) 2015-10-29
JP2012514466A (ja) 2012-06-28
AU2010204178A1 (en) 2011-09-01
US8796218B2 (en) 2014-08-05
CN102348721A (zh) 2012-02-08
CA2752490A1 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
CA2752490C (en) Alpha-lactablumin complex with oleic acid and process for production thereof
Kheterpal et al. Structural features of the Aβ amyloid fibril elucidated by limited proteolysis
Choma et al. Asparagine-mediated self-association of a model transmembrane helix
Lees et al. Structure and function of proteolipids in myelin and non-myelin membranes
Shinchuk et al. Poly‐(L‐alanine) expansions form core β‐sheets that nucleate amyloid assembly
Gibson et al. Design of peptidyl compounds that affect β-amyloid aggregation: importance of surface tension and context
Moore et al. Biophysical analyses of synthetic amyloid-β (1− 42) aggregates before and after covalent cross-linking. implications for deducing the structure of endogenous amyloid-β oligomers
Schrattenholz et al. Expression and renaturation of the N-terminal extracellular domain of Torpedo nicotinic acetylcholine receptor α-subunit
KR20190092472A (ko) 나노입자 제제
Roy et al. Synaptobrevin transmembrane domain dimerization revisited
Ramirez et al. Nuclear magnetic resonance-based structural characterization and backbone dynamics of recombinant bee venom melittin
Britton et al. Supramolecular assembly and small-molecule binding by protein-engineered coiled-coil fibers
Jayaraman et al. Impact of self-association on function of apolipoprotein AI
Bascetin et al. Amyloid-like aggregates formation by blood plasma fibronectin
Thiaudiere et al. Structural characterization of membrane insertion of M13 procoat, M13 coat, and Pf3 coat proteins
Francis et al. The single C‐terminal helix of human phospholipid scramblase 1 is required for membrane insertion and scrambling activity
JP4233114B2 (ja) フォン・ブィレブランド因子の治療用フラグメント
KR20200038507A (ko) 헤모펙신 제형
Yamaguchi et al. Extension of Aβ2M amyloid fibrils with recombinant human β2-microglobulin
Hiramatsu et al. Differences in the molecular structure of β2-microglobulin between two morphologically different amyloid fibrils
Doucet et al. Gel formation of peptides produced by extensive enzymatic hydrolysis of β-lactoglobulin
Hesler et al. Structure-function analysis of plasma cholesteryl ester transfer protein by protease digestion and expression of cDNA fragments in Escherichia coli
Jablonowska et al. Alzheimer's disease Aβ peptide fragment 10–30 forms a spectrum of metastable oligomers with marked preference for N to N and C to C monomer termini proximity
JP4354956B2 (ja) Ｐｈ依存性のポリペプチド凝集およびその使用
CN108264547B (zh) 一种纯化蛋白的方法以及试剂盒

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150107

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241230

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241230